Table 2.
Summary of initial success rates of BRCA1/2 sequencing based on clinical–pathologic variables.
| Clinical–Pathologic Variables | Complete | Failed | Indeterminate | Total | p-Value (Pearson Chi-Square) | |
|---|---|---|---|---|---|---|
| Sample type | Surgical | 206 (81.4%) | 15 (5.9%) | 32 (12.7%) | 253 (87%) | 0.001 |
| Biopsy | 20 (57.1%) | 9 (25.7%) | 6 (17.2%) | 35 (12%) | ||
| Cytology | 2 (66.7%) | 1 (33.3%) | 0 | 3 (1%) | ||
| Tumor cellularity | ≥50% | 185 (81.9%) | 9 (4.0%) | 32 (14.1%) | 226 (77.7%) | <0.0001 |
| >10% to <50% | 34 (73.9%) | 7 (15.2%) | 5 (10.9%) | 46 (15.8%) | ||
| ≤10% | 9 (47.4%) | 9 (47.4%) * | 1 (5.2%) | 19 (6.5%) | ||
| Tumor size | ≥10 mm | 206 (79.5%) | 17 (6.6%) | 36 (13.9%) | 259 (89%) | <0.0001 |
| 5–9 mm | 13 (92.9%) | 1 (7.1%) | 0 | 14 (4.8%) | ||
| ≤4 mm | 9 (50.0%) | 7 (38.9%) | 2 (11.1%) | 18 (6.2%) | ||
| Chemotherapy | Yes | 64 (75.3%) | 9 (10.6%) | 12 (14.1%) | 85 (29.2%) | 0.669 |
| No | 164 (79.6%) | 16 (7.8%) | 26 (12.6%) | 206 (70.8%) | ||
| Age of tissue block, years | <3 | 111 (75.5%) | 13 (8.8%) | 23 (15.7%) | 147 (50.5%) | 0.396 |
| ≥3 | 117 (81.3%) | 12 (8.3%) | 15 (10.4%) | 144 (49.5%) | ||
| Total | 228 (78.4%) | 25 (8.6%) | 38 (13.0%) | 291 (100%) | ||
* 9 samples with insufficient tumor.